PA-LINESIGHT
18.10.2021 16:02:05 CEST | Business Wire | Press release
IPS-Integrated Project Services, LLC , headquartered in Blue Bell, Pennsylvania and a subsidiary of Alleghany Capital Corporation , today announced that it has acquired Linesight, a multinational consulting firm headquartered in Dublin, Ireland. IPS is a large EPCMV (Engineering, Procurement, Construction Management and Validation) company with over 1,700 staff across 22 offices worldwide. Linesight is a fast-growing professional consultancy services organization providing project controls to data center providers, life sciences companies, commercial real estate, healthcare, hospitality, retail and residential sectors. Linesight has over 900 staff across 24 offices globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005645/en/
The acquisition is being approached as a future integrated partnership where IPS will leverage Linesight’s experience and expertise in particular in the data center sector and Linesight in turn will leverage IPS’s expertise in the Life Sciences sector. Both organizations will expand their geographic reach, build on their bench strength and extend their service propositions for their target clients globally. Linesight will continue to serve its clients as it always has, but now has the support of a much larger organization behind it.
Dave Goswami, CEO, IPS stated “This is a transformational transaction for both IPS and Linesight and we are excited to embark on a new growth journey together, supported by Alleghany Capital. By leveraging both companies’ strong track records and combining our skills and management horsepower, we expect to make a meaningful positive difference in the industries we serve. Led by Paul Boylan and a strong leadership team, Linesight is a highly sought after company providing consulting services, including cost and project management, project controls, risk, scheduling and procurement services focused on the data center, life sciences, and other industry sectors.
This fits well with IPS’ complementary services which include engineering, construction management and compliance services. We are thrilled at the prospect of working with the Linesight team to provide a more comprehensive and superior suite of services to our respective clients.”
Paul Boylan, CEO, Linesight added, “This is a pivotal point in Linesight’s long and successful business history and will enable us to deliver on our ambitious strategic plans, expand into new geographies to better service our client needs and extend our portfolio offering in our existing and new target markets. Linesight’s skilled teams will continue to provide the same high-quality levels of service to our clients globally and we see enhanced career opportunities for our people in all our regions. I am energized at the potential of this new business partnership and believe that it positions us well to deliver on our ambitious growth aspirations as we look towards 2022 and beyond.”
About IPS-Integrated Project Services
IPS is a global leader in developing innovative business solutions for the biotechnology and pharmaceutical industries. Through operational expertise and industry-leading knowledge, skill and passion, IPS provides consulting, architecture, engineering, construction management, and compliance services that allow clients to create and manufacture life-impacting products around the world. Headquartered in Blue Bell, Pennsylvania in the United States, IPS is one of the fastest-growing companies servicing the life sciences industry with over 1,700 professionals in the United States, Canada, Brazil, the United Kingdom, Ireland, Switzerland, Singapore, China, and India. For more information about IPS, please visit www.ipsdb.com
.
About Linesight
Linesight is a multinational consultancy firm with over 45 years' experience, providing cost, schedule, risk, program and project management services to a multitude of sectors including Data Centers, Life Sciences, Commercial, High-Tech Industrial, Residential, Hospitality, Healthcare and Retail. Linesight’s specialist project teams, each with specific skills and experience, provide better predictability of project outcomes, faster project delivery, greater cost efficiency and maximum value for money for its clients. For further information, please visit http://www.linesight.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005645/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom